Tonghuashun (300033) Financial Research Center, May 13. Some investors asked Watson Biotech (300142)(300142). In early May this year, the World Health Organization had put KPgoldencrownpoker.2 Subvarieties are listed as variants under monitoring. According to the latest data released by the Centers for Disease Control and Prevention (CDC), the main variant spreading in the United States today is the "FLiRT" group led by KP.2, of which the proportion of KP.2 infections has reached 25%. May I ask if the mRNA vaccine developed by your company is effective against the above variantsgoldencrownpoker?
The company replied, Hello, Dear Investor! As of April, the latest data released by the Chinese Center for Disease Control and Prevention show that the KP.2 COVID-19 variant has not spread widely in China. The KP.2 variant is a derivative of JN.1. From a technical perspective, previous infection and XBB vaccine vaccination should have a cross-effect on immune protection of the JN.1 variant. Thank you!